Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals (ICPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,114,470
  • Shares Outstanding, K 32,992
  • Annual Sales, $ 252,000 K
  • Annual Income, $ -344,680 K
  • 60-Month Beta 1.85
  • Price/Sales 3.69
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ICPT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -1.55
  • Number of Estimates 11
  • High Estimate -1.24
  • Low Estimate -1.80
  • Prior Year -2.99
  • Growth Rate Est. (year over year) +48.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.78 +54.64%
on 01/04/21
38.94 -5.55%
on 01/27/21
+9.99 (+37.29%)
since 12/24/20
3-Month
23.78 +54.64%
on 01/04/21
40.41 -8.98%
on 11/11/20
+7.86 (+27.18%)
since 10/27/20
52-Week
23.78 +54.64%
on 01/04/21
99.89 -63.18%
on 02/05/20
-56.15 (-60.42%)
since 01/27/20

Most Recent Stories

More News
Intercept Company Statement on Analyst Note

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

ICPT : 37.23 (+10.21%)
Intercept Appoints Jared M. Freedberg as General Counsel and Secretary

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

GILD : 65.53 (-1.75%)
IMMU : 87.86 (+0.05%)
ICPT : 37.23 (+10.21%)
Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

JPM : 127.79 (-2.88%)
ICPT : 37.23 (+10.21%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ICPT, BSX and QIWI

NEW YORK, NY / ACCESSWIRE / January 4, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate...

ICPT : 37.23 (+10.21%)
BSX : 35.77 (-2.37%)
QIWI : 10.00 (-2.06%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2021 - ICPT

New York, New York--(Newsfile Corp. - January 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

ICPT : 37.23 (+10.21%)
ICPT INVESTOR DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Filed Against Intercept Pharmaceuticals, Inc.

, /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has...

ICPT : 37.23 (+10.21%)
ICPT Final Deadline Today: Rosen, National Trial Lawyers, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - ICPT

New York, New York--(Newsfile Corp. - January 4, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...

ICPT : 37.23 (+10.21%)
Lawsuits Filed Against ICPT, HPQ and LRN - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / January 4, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who...

ICPT : 37.23 (+10.21%)
HPQ : 24.99 (+1.50%)
LRN : 24.91 (-4.16%)
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

, /PRNewswire/ -- , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ: ) for...

ICPT : 37.23 (+10.21%)
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ICPT, HPQ and GDRX

NEW YORK, NY / ACCESSWIRE / January 4, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies....

ICPT : 37.23 (+10.21%)
HPQ : 24.99 (+1.50%)
GDRX : 50.62 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR)....

See More

Key Turning Points

3rd Resistance Point 37.93
2nd Resistance Point 36.55
1st Resistance Point 35.16
Last Price 37.23
1st Support Level 32.40
2nd Support Level 31.02
3rd Support Level 29.63

See More

52-Week High 99.89
Fibonacci 61.8% 70.82
Fibonacci 50% 61.84
Fibonacci 38.2% 52.86
Last Price 37.23
52-Week Low 23.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar